Open AccessAssociation of lipoprotein(a) with long‐term mortality following coronary angiography or percutaneous coronary intervention
Author(s) -
Feng Zhe,
Li Hualong,
Bei Weijie,
Guo Xiaosheng,
Wang Kun,
Yi Shixin,
Luo Demou,
Li Xida,
Chen Shiqun,
Ran Peng,
Chen Pengyuan,
Islam Sheikh Mohammed Shariful,
Chen Jiyan,
Liu Yong,
Zhou Yingling
Publication year - 2017
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.22712
Subject(s) - medicine , conventional pci , percutaneous coronary intervention , hazard ratio , confidence interval , lipoprotein(a) , confounding , cardiology , proportional hazards model , coronary angiography , lipoprotein , myocardial infarction , cholesterol
Background There is no consistent evidence to suggest the association of plasma lipoprotein(a) (Lp[a]) with long‐term mortality in patients undergoing coronary angiography ( CAG ) or percutaneous coronary intervention ( PCI ). Hypothesis Level of Lp(a) is associated with long‐term mortality following CAG or PCI . Methods We enrolled 1684 patients with plasma Lp(a) data undergoing CAG or PCI between April 2009 and December 2013. The patients were divided into 2 groups: a low‐Lp(a) group (Lp[a] <16.0 mg/ dL ; n = 842) and a high‐Lp(a) group (Lp[a] ≥16.0 mg/ dL ; n = 842). Results In‐hospital mortality was not significantly different between the high and low Lp(a) groups (0.8% vs 0.5%, respectively; P = 0.364). During the median follow‐up period of 1.95 years, the high‐Lp(a) group had a higher long‐term mortality than did the low‐Lp(a) group (5.8% vs 2.5%, respectively; P = 0.003). After adjustment of confounders, multivariate Cox regression analysis revealed that a higher Lp(a) level was an independent predictor of long‐term mortality (hazard ratio: 1.96, 95% confidence interval: 1.07‐3.59, P = 0.029). Conclusions Our data suggested that an elevated Lp(a) level was significantly associated with long‐term mortality following CAG or PCI . However, additional larger multicenter studies will be required to investigate the predictive value of Lp(a) levels and evaluate the benefit of controlling Lp(a) levels for patients undergoing CAG or PCI .